Skip to main content

Table 4 Ongoing randomised second-line trials with selected immunotherapeuticsa in recurrent and/or metastatic head and neck cancer (also including nasopharyngeal carcinoma) as of April 2017 (≥ 100 patients)

From: Immunotherapy in head and neck cancer: aiming at EXTREME precision

Trial, ClinicalTrials.gov identifier Phase Estimated enrolment Immunotherapeutic approach Regimen (treatment arms A, B, C) Primary completion date
NCT02105636
(CheckMate-141)
III 361d Anti-PD-1 A: Nivolumab
B: SoC
11/2015
NCT02319044
(CONDOR)b
IIR 240 Anti-PD-L1
Anti-CTLA-4
A: Durvalumab
B: Tremelimumab
C: Durvalumab + tremelimumab
9/2016
NCT02252042
(KEYNOTE-040)
III 466 Anti-PD-1 A: Pembrolizumab
B: SoC
5/2017
NCT02369874
(EAGLE)
III 720 Anti-PD-L1
Anti-CTLA-4
A: Durvalumab
B: Durvalumab + tremelimumab
C: SoC
2/2018
NCT02611960c
(KEYNOTE-122)
IIR 160 Anti-PD-1 A: Pembrolizumab
B: SoC
1/2019
  1. IIR phase II randomised, PD-1 programmed cell death protein-1, PD-L1 programmed cell death ligand-1, CTLA-4 cytotoxic T-lymphocyte antigen-4, SoC Standard of Care
  2. aimmune-modulating agents, vaccines, and adoptive T-cell transfer
  3. bin patients with PD-L1 negative tumours
  4. conly nasopharyngeal cancer
  5. dactual and estimated enrolments were 361 and 506, respectively
\